Key result
Stent thrombosis remains an uncommon but potentially catastrophic complication of percutaneous coronary intervention, with ongoing research focused on optimal antiplatelet therapy and novel stent designs.
This review highlights the incidence, predictors, and ongoing research into dual antiplatelet therapies and novel stent technologies to minimize the risk of stent thrombosis.
Stent thrombosis warrants vigilant post-PCI monitoring; leaves open optimal antiplatelet regimens and stent technologies pending prospective trials.
Some concerns have been raised regarding the risk of late and very late stent thrombosis (ST) following drug-eluting stent implantation. Despite remaining an uncommon complication of percutaneous coronary intervention, when ST occurs, it can be catastrophic to the individual, commonly presenting as acute ST elevation myocardial infarction or sudden cardiac death. The incidence and predictors of ST have been reported in the literature and the role of dual antiplatelet therapies in the avoidance of such a complication remains vital. Ongoing studies are assessing the role of these therapies including platelet reactivity testing, genetic testing and optimum duration of therapy. In addition, newer polymer-free and bioabsorbable stents are under investigation in the quest to potentially minimise the risk of ST.
No takes yet. Share an insight, caveat, or question.
Buchanan et al. (2012) conducted a review in Stent thrombosis following drug-eluting stent implantation. Stent thrombosis remains an uncommon but potentially catastrophic complication of percutaneous coronary intervention, with ongoing research focused on optimal antiplatelet therapy and novel stent designs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: